Bannister, Jim R.Khan, Abdul L.Eccleston, David W.Deol-Poonia, Ranjeev K.Hughes, Stephen F.2016-03-312016-03-312012-12-30Bannister, J. R., Khan, A. L., Eccleston, D. W., Deol-Poonia, R. K., & Hughes, S. F. (2012). Interleukin-17 Expression in the Barrett’s Metaplasia-Dysplasia-Adenocarcinoma Sequence. ISRN Inflammation, 2012, Article number 578149. https://doi.org/10.5402/2012/57814910.5402/2012/578149http://hdl.handle.net/10034/604068Original Research ArticleThis pilot study evaluated the expression of the proinflammatory cytokine IL-17 along the Barrett’s metaplasia-dysplasia-adenocarcinoma sequence by establishing the expression levels of IL-17 in columnar epithelium, intestinal metaplastic cells, and dysplastic/glandular neoplastic cells. Immunohistochemical techniques were used to examine the accumulation of the proinflammatory cytokine IL-17 in forty () formalin-fixed, paraffin-embedded oesophageal archived specimens across a range of endoscopic diagnostic categories, and a highly significant difference was found, where , in IL-17 expression (Kruskall Wallis and Mann-Whitney ) between all the cell types examined. There was also a strong positive correlation (Spearman's rank correlation) between disease progression and IL-17 expression (, , ), IL-17 expression was absent or absent/weak in columnar epithelium, weak to moderate in columnar metaplastic cells, and moderate to strong in dysplastic/neoplastic cells, which demonstrated that the elevation of IL-17 expression occurs in the progression of the disease. Understanding the differential expression of IL-17 between benign and malignant tissue potentially has a significant diagnostic, prognostic, and therapeutic value. Ultimately, this selective biomarker may be employed in routine clinical practice for the screening of oesophageal adenocarcinoma.enCancerbiomarkerArticle2090-8695ISRN Inflammation